Intensity Therapeutics Reports Q2 2026 Financial Results

What Happened

• Intensity Therapeutics, Inc. announced on August 11, 2026 that it released its financial results for the three and six months ended June 30, 2026. The company filed a Current Report on Form 8-K (Item 2.02) to disclose this release and attached the related press release as Exhibit 99.1. The report was signed by CEO Lewis H. Bender.

Key Details

• Date of release: August 11, 2026.
• Reporting periods covered: three and six months ended June 30, 2026.
• Press release included as Exhibit 99.1 and referenced in the 8-K; a Cover Page Interactive Data File (Inline XBRL) is included as Exhibit 104.
• The 8-K notes the attached material is furnished (not “filed”) for purposes of Section 18 of the Exchange Act and includes a forward‑looking statement caution referencing the company's 2026 10‑K and 10‑Q filings.

Why It Matters

• For investors, the 8-K signals the company has published its latest quarterly results (earnings/quarterly results) — the press release will contain the specific financial metrics (revenue, net loss/gain, cash position, and any commentary on operations or guidance).
• The filing’s forward‑looking statement caution points investors to the company’s previously filed risk disclosures (10‑K and 10‑Qs) for factors that could affect future performance. Investors should review the attached press release and the company’s subsequent SEC filings for full details before making decisions.